Short Interest in GoodRx Holdings, Inc. (NASDAQ:GDRX) Declines By 33.7%

GoodRx Holdings, Inc. (NASDAQ:GDRX) was the recipient of a large decrease in short interest in the month of May. As of May 29th, there was short interest totaling 7,218,628 shares, a decrease of 33.7% from the May 14th total of 10,887,679 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average daily trading volume, of 1,769,530 shares, the days-to-cover ratio is presently 4.1 days.

GoodRx Trading Down 4.4%

NASDAQ:GDRX opened at $2.61 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.47. The firm has a market capitalization of $894.11 million, a price-to-earnings ratio of 43.51, a price-to-earnings-growth ratio of 1.26 and a beta of 1.61. GoodRx has a one year low of $1.77 and a one year high of $5.81. The business has a fifty day moving average price of $2.54 and a 200-day moving average price of $2.48.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The business had revenue of $194.01 million during the quarter, compared to analyst estimates of $185.40 million. During the same quarter in the prior year, the business posted $0.09 EPS. GoodRx’s revenue for the quarter was down 4.4% compared to the same quarter last year. Sell-side analysts forecast that GoodRx will post 0.17 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GDRX shares. Citigroup increased their price target on GoodRx from $3.50 to $4.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Weiss Ratings lowered GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 20th. Leerink Partners restated an “outperform” rating and issued a $3.00 price objective on shares of GoodRx in a research note on Thursday, February 26th. The Goldman Sachs Group restated a “neutral” rating and issued a $3.50 price objective on shares of GoodRx in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of GoodRx in a research note on Friday, February 27th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, GoodRx has an average rating of “Hold” and an average target price of $3.81.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GDRX. Prescott Group Capital Management L.L.C. purchased a new position in shares of GoodRx during the fourth quarter valued at about $4,812,000. Northwestern Mutual Wealth Management Co. grew its position in shares of GoodRx by 10,242.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock valued at $4,072,000 after purchasing an additional 1,488,137 shares in the last quarter. AQR Capital Management LLC grew its position in shares of GoodRx by 188.0% during the fourth quarter. AQR Capital Management LLC now owns 1,158,546 shares of the company’s stock valued at $3,140,000 after purchasing an additional 756,209 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of GoodRx by 7.3% in the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock valued at $38,947,000 after acquiring an additional 624,182 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of GoodRx in the 4th quarter valued at about $1,585,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.